{"id":"sd-809","safety":{"commonSideEffects":[{"rate":null,"effect":"Parkinsonism"},{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Depression"},{"rate":null,"effect":"Anxiety"}]},"_chembl":{"chemblId":"CHEMBL1529736","moleculeType":"Small molecule","molecularWeight":"272.10"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting VMAT2, SD-809 depletes intracellular stores of dopamine, serotonin, and norepinephrine, leading to reduced neurotransmitter availability in the synapse. This mechanism is thought to reduce involuntary movements and hyperkinetic symptoms. The drug crosses the blood-brain barrier to exert central nervous system effects.","oneSentence":"SD-809 is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor that reduces the packaging and release of monoamines in presynaptic neurons.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:33:40.524Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tardive dyskinesia"},{"name":"Chorea associated with Huntington's disease"}]},"trialDetails":[{"nctId":"NCT06997198","phase":"PHASE4","title":"Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities","status":"NOT_YET_RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2026-03-01","conditions":"Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities","enrollment":25},{"nctId":"NCT04713982","phase":"PHASE2, PHASE3","title":"Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-11-19","conditions":"Huntington Disease","enrollment":30},{"nctId":"NCT07105111","phase":"PHASE4","title":"A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor","status":"RECRUITING","sponsor":"Neurocrine Biosciences","startDate":"2025-08-29","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar Disorder","enrollment":50},{"nctId":"NCT04301726","phase":"PHASE1","title":"Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HD","status":"TERMINATED","sponsor":"Fundacion Huntington Puerto Rico","startDate":"2022-01-21","conditions":"Huntington Disease","enrollment":36},{"nctId":"NCT04173260","phase":"PHASE1, PHASE2","title":"An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2021-04-29","conditions":"Dystonia, Primary","enrollment":15},{"nctId":"NCT04200352","phase":"PHASE3","title":"A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2020-02-04","conditions":"Cerebral Palsy, Dyskinetic","enrollment":44},{"nctId":"NCT03813238","phase":"PHASE3","title":"A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2019-08-06","conditions":"Cerebral Palsy, Dyskinetic","enrollment":63},{"nctId":"NCT02198794","phase":"PHASE3","title":"Reducing Involuntary Movements in Participants With Tardive Dyskinesia","status":"COMPLETED","sponsor":"Auspex Pharmaceuticals, Inc.","startDate":"2014-10-20","conditions":"Tardive Dyskinesia","enrollment":343},{"nctId":"NCT02674321","phase":"PHASE1","title":"A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)","status":"COMPLETED","sponsor":"Auspex Pharmaceuticals, Inc.","startDate":"2014-07","conditions":"TOURETTE SYNDROME","enrollment":23},{"nctId":"NCT01897896","phase":"PHASE3","title":"Alternatives for Reducing Chorea in Huntington Disease","status":"COMPLETED","sponsor":"Auspex Pharmaceuticals, Inc.","startDate":"2013-11-12","conditions":"Chorea Associated With Huntington Disease","enrollment":119},{"nctId":"NCT03571256","phase":"PHASE3","title":"A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2018-05-31","conditions":"Tourette Syndrome","enrollment":158},{"nctId":"NCT02195700","phase":"PHASE2, PHASE3","title":"Aim to Reduce Movements in Tardive Dyskinesia","status":"COMPLETED","sponsor":"Auspex Pharmaceuticals, Inc.","startDate":"2014-06","conditions":"Tardive Dyskinesia","enrollment":117},{"nctId":"NCT03567291","phase":"PHASE3","title":"Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2018-05-25","conditions":"Tourette Syndrome","enrollment":228},{"nctId":"NCT03452943","phase":"PHASE2, PHASE3","title":"Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2018-02-05","conditions":"Tourette Syndrome","enrollment":119},{"nctId":"NCT02291861","phase":"PHASE3","title":"Addressing Involuntary Movements in Tardive Dyskinesia","status":"COMPLETED","sponsor":"Auspex Pharmaceuticals, Inc.","startDate":"2014-10-31","conditions":"Tardive Dyskinesia","enrollment":298},{"nctId":"NCT04071639","phase":"PHASE1","title":"Symptomatic Therapy for Patients With Huntington's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-03-12","conditions":"Huntington Disease","enrollment":60},{"nctId":"NCT01795859","phase":"PHASE3","title":"First Time Use of SD-809 in Huntington Disease","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-08-05","conditions":"Chorea","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Deutetrabenazine; TEV-50717","deutetrabenzine","Austedo","deutetrabenazine","Deutetrabenazine"],"phase":"phase_3","status":"active","brandName":"SD-809","genericName":"SD-809","companyName":"Auspex Pharmaceuticals, Inc.","companyId":"auspex-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SD-809 is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor that reduces the packaging and release of monoamines in presynaptic neurons. Used for Tardive dyskinesia, Chorea associated with Huntington's disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":5,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}